References of "Rovati, Lucio"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCan we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers ans frailty
Arden, Nigel; Richette, Pascal; Cooper, Cyrus et al

in Drugs & Aging (2015), 32

Osteoarthritis (OA), a disease affecting different patient phenotypes, appears as an optimal candidate for personalized healthcare. The aim of the discussions of the European Society for Clinical and ... [more ▼]

Osteoarthritis (OA), a disease affecting different patient phenotypes, appears as an optimal candidate for personalized healthcare. The aim of the discussions of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group was to explore the value of markers of different sources in defining different phenotypes of patients with OA. The ESCEO organized a series of meetings to explore the possibility of identifying patients who would most benefit from treatment for OA, on the basis of recent data and expert opinion. In the first meeting, patient phenotypes were identified according to the number of affected joints, biomechanical factors, and the presence of lesions in the subchondral bone. In the second meeting, summarized in the present article, the working group explored other markers involved in OA. Profiles of patients may be defined according to their level of pain, functional limitation, and presence of coexistent chronic conditions including frailty status. A considerable amount of data suggests that magnetic resonance imaging may also assist in delineating different phenotypes of patients with OA. Among multiple biochemical biomarkers identified, none is sufficiently validated and recognized to identify patients who should be treated. Considerable efforts are also being made to identify genetic and epigenetic factors involved in OA, but results are still limited. The many potential biomarkers that could be used as potential stratifiers are promising, but more research is needed to characterize and qualify the existing biomarkers and to identify new candidates. [less ▲]

Detailed reference viewed: 39 (5 ULg)
Full Text
Peer Reviewed
See detailHealth claims assessment in the field of joint and cartilage: a consensus viewpoint of the Group for the Respect of Ethics and Excellence in Science
Bruyère, Olivier ULg; Avouac, Bernard; Richette, Pascal et al

in Current Medical Research & Opinion (2012), 28(4), 611-6

Abstract Introduction: In 2006, the European Parliament and Council issued a regulation (No. 1924/2006) for the nutrition and health claims made on foods, including food supplements. According to the ... [more ▼]

Abstract Introduction: In 2006, the European Parliament and Council issued a regulation (No. 1924/2006) for the nutrition and health claims made on foods, including food supplements. According to the regulation, the use of nutrition and health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect. In the field of joint and cartilage health, there is no clear scientific-based definition of the nature of such a beneficial nutritional or physiological effect. The objective of this paper is to scientifically define the possible content of health claims related to joint and cartilage health and to provide scientific guidelines for the design of clinical studies which need to be adopted to substantiate such health claims. Methods: Literature review up to September 2011 followed by a consensus expert discussion organized by the Group for the Respect of Ethics and Excellence in Science (GREES). Results: In line with the general principles of the PASSCLAIM and the Codex recommendations, the GREES identified four acceptable health claims related to joint and cartilage health based on the effects on discomfort, joint and cartilage structural integrity or risk factors for joint and cartilage diseases. The GREES considers that randomized controlled trials on a relevant outcome is the best design to assess health claims. Moreover, animal studies could also be of interest to substantiate some health claims, to assess the clinical relevance of endpoints used in human studies or to extrapolate data obtained in patients to the target (apparently) healthy population. Conclusion: According to the methodology and biomarkers used in the study and whether or not additional animal studies are provided to support the claim, various health claims can be acceptable in the field of joint and cartilage health. [less ▲]

Detailed reference viewed: 28 (9 ULg)
Full Text
Peer Reviewed
See detailGlucosamine sulfate in the treatment of knee osteoarthritis: impact on health utility.
Scholtissen, S.; Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg et al

in Osteoporosis International (2009, March), 20(Suppl.1), 149

Detailed reference viewed: 36 (11 ULg)
Full Text
Peer Reviewed
See detailEffect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies.
Scholtissen, S.; Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg et al

in Osteoporosis International (2009, March), 20(Suppl.1), 18

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailClinical severity of knee osteoarthritis poorly predicts long-term radiographic outcomes
Bruyère, Olivier ULg; Ethgen, Olivier ULg; Lejeune, Eric ULg et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 153

Detailed reference viewed: 11 (5 ULg)